Sakai K, Sinha A A, Mitchell D J, Zamvil S S, Rothbard J B, McDevitt H O, Steinman L
Department of Neurology, Stanford University, CA 94305.
Proc Natl Acad Sci U S A. 1988 Nov;85(22):8608-12. doi: 10.1073/pnas.85.22.8608.
The peptide p89-101 (Val-His-Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro) of myelin basic protein is encephalitogenic in mice expressing H-2q and H-2s antigens. Six of 13 encephalitogen-specific T-cell clones were shown to express the variable beta-chain (V beta) 17a gene product (KJ23a+), whereas seven clones were KJ23a-. Both KJ23a+ and KJ23a- subpopulations were encephalitogenic in SJL/J mice when adoptively transferred. Depletion of KJ23a+ cells in vivo with the administration of the antibody KJ23a suppresses experimental allergic encephalomyelitis induced with KJ23a+ T-cell lines. However, experimental allergic encephalomyelitis induced with either (i) encephalitogenic peptide p89-101, (ii) intact myelin basic protein, or (iii) KJ23a- T cells reactive to p89-101 cannot be prevented with monoclonal antibody KJ23a. These data indicate that in spite of the V beta 17a gene expression in a relatively large proportion of p89-101-specific T cells, such V beta gene use is not essential for the induction of experimental allergic encephalomyelitis in SJL/J mice. These results contrast with the predominance of V beta gene use (V beta 8.2) in T cells reactive to the encephalitogenic fragment (pR1-11) in PL/J mice. One reason for this lack of dominant use of a particular T-cell receptor V beta gene family in the autoimmune response to myelin basic protein in SJL/J mice stems from the observation that two encephalitogenic epitopes exist in p89-101. KJ23a- T cells are stimulated by the deleted peptide p89-100, whereas KJ23a+ T cells are not. Thus, in the response to an encephalitogenic fragment of myelin basic protein containing two nested epitopes, at least two distinct T-cell receptor V beta genes are expressed. These distinct T-cell subpopulations can each trigger experimental allergic encephalomyelitis. These findings have implications for therapy of autoimmune disease with antibodies to the T-cell receptor gene products.
髓鞘碱性蛋白的肽段p89 - 101(Val - His - Phe - Phe - Lys - Asn - Ile - Val - Thr - Pro - Arg - Thr - Pro)在表达H - 2q和H - 2s抗原的小鼠中具有致脑炎性。13个致脑炎原特异性T细胞克隆中有6个显示表达可变β链(Vβ)17a基因产物(KJ23a +),而7个克隆为KJ23a -。当进行过继转移时,KJ23a +和KJ23a -亚群在SJL/J小鼠中均具有致脑炎性。通过给予抗体KJ23a在体内耗尽KJ23a +细胞可抑制由KJ23a + T细胞系诱导的实验性变应性脑脊髓炎。然而,用单克隆抗体KJ23a无法预防由以下任何一种诱导的实验性变应性脑脊髓炎:(i)致脑炎原肽p89 - 101,(ii)完整的髓鞘碱性蛋白,或(iii)对p89 - 101有反应的KJ23a - T细胞。这些数据表明,尽管在相对较大比例的p89 - 101特异性T细胞中表达了Vβ17a基因,但这种Vβ基因的使用对于在SJL/J小鼠中诱导实验性变应性脑脊髓炎并非必不可少。这些结果与PL/J小鼠中对致脑炎片段(pR1 - 11)有反应的T细胞中Vβ基因使用(Vβ8.2)占主导形成对比。SJL/J小鼠在对髓鞘碱性蛋白的自身免疫反应中缺乏对特定T细胞受体Vβ基因家族的主导使用,其一个原因源于观察到p89 - 101中存在两个致脑炎表位。缺失的肽段p89 - 100可刺激KJ23a - T细胞,而KJ23a + T细胞则不然。因此,在对包含两个嵌套表位的髓鞘碱性蛋白致脑炎片段的反应中,至少表达了两种不同的T细胞受体Vβ基因。这些不同的T细胞亚群各自均可引发实验性变应性脑脊髓炎。这些发现对于用针对T细胞受体基因产物的抗体治疗自身免疫性疾病具有启示意义。